Module 10 - Precision Medicine: Evidence-Based Development and Practice: IV. Immunocarcinogenesis Breast Cancer Subtyping

Precision Medicine: Evidence-Based Development and Practice: IV. Immunocarcinogenesis Breast Cancer Subtyping is organized by Persona Biomed, Inc.

Course Overview and Goals:
Precision Medicine comprises customized diagnostic and therapeutic strategies targeting patients with susceptibility to a distinct disease condition based on individualized and family genomic background, environmental effects, lifestyle habits and co-morbidities.

It is an emerging clinical field that integrates broadly validated results from investigations of molecular and genetic basis of diseases with prevention, diagnosis and treatment of the individual patient. It is also a necessary aspiration if we are to achieve a health care delivery system that can provide accessible, high-quality, and cost/effective clinical care.

While it has tremendous potential to contribute to improving outcomes and decreasing cost of treatments, there remain important challenges to its clinical implementation that need attention, including: Education of physicians for successfully transition to using Precision Medicine at their medical practice; Integrating molecular and genetic guidance into routine healthcare delivery; Securing patient engagement and trust; Regulating Laboratory Developed Tests (LDTs) and targeted therapies; Generating the evidentiary support for Precision Medicine; Data-sharing and infrastructure needs; Economics of Precision Medicine and the new business models that simultaneously reduce the cost but improve the quality of care.

On this basis, this course has been mainly designed to meet the educational needs of physicians and other healthcare providers who see patients and have the desire of understanding newest concepts, methods and procedures of Precision Medicine, its cost-effectiveness and its distinct business model, commercialization channels and reimbursement.

Program of Lectures:

Educational Objectives:
Precision Medicine: Evidence-Based Development and Practice (IV. Immunocarcinogenesis Breast Cancer Subtyping)
• State biological and therapeutical aspects of breast cancer and breast cancer metastasis disease.
• Molecular classifications and therapeutic targets in breast cancer Precision Medicine.
• Describe clinical and therapeutical implications of breast cancer molecular subtyping by immune checkpoint genes and her2-regulated prometastatic genes.